SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)

被引：0
|
作者：
Dimopoulos, M. [1 ]
Trotman, J. [2 ]
Tedeschi, A. [3 ]
Matous, J. V. [4 ]
Macdonald, D. [5 ]
Tam, C. [6 ,7 ]
Tournilhac, O. [8 ]
Ma, S. [9 ]
Oriol, A. [10 ]
Heffner, L. [11 ]
Shustik, C. [12 ]
Garcia-Sanz, R. [13 ]
Cornell, R. F. [14 ]
Fernandez de Larrea, C. [15 ]
Castillo, J. J. [16 ]
Granell, M. [17 ]
Kyrtsonis, M. C. [18 ]
Leblond, V. [17 ,19 ]
Symeonidis, A. [20 ]
Singh, P. [21 ]
Li, J. [21 ]
Graef, T. [21 ]
Bilotti, E. [21 ]
Treon, S. [16 ]
Buske, C. [22 ]
机构：
[1] Univ Athens, Sch Med, Athens 11528, Greece
[2] Univ Sydney, Concord Hosp, Sydney, NSW 2006, Australia
[3] Osped Niguarda Ca Granda, Milan, Italy
[4] Colorado Blood Canc Inst, Denver, CO USA
[5] Dalhousie Univ, Halifax, NS, Canada
[6] Peter MacCallum Canc Ctr, Melbourne, Australia
[7] St Vincents Hosp, Melbourne, Australia
[8] CHU Clermont Ferrand, Hematol Clin Adulte & Therapie Cellulaire, Clermont Ferrand, France
[9] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[10] Hosp Badalona Germans Trias & Pujol, Catala Oncol 9Inst, Barcelona, Spain
[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[12] McGill Univ Hlth Ctr, Royal Victoria Hosp, Montreal, PQ, Canada
[13] Hosp Univ Salamanca, Salamanca, Spain
[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[15] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain
[16] Dana Farber Canc Inst, Boston, MA 02115 USA
[17] Hosp Sant Pau, Barcelona, Spain
[18] Univ Athens, Athens 11528, Greece
[19] UPMC Univ Paris, Hop Pitie Salpetriere APHP, Paris, France
[20] Univ Patras, Medial Sch, Patras, Greece
[21] AbbVie Co, Pharmacyclics LLC, Sunnyvale, CA USA
[22] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, INNOVATE TM Study Grp, Ulm, Germany
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P652
引用
收藏
页码：256 / 257
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenstrom's macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE™)
    Dimopoulos, M. A.
    Trotman, J.
    Tedeschi, A.
    Matous, J. V.
    Macdonald, D.
    Tam, C.
    Tournilhac, O.
    Ma, S.
    Oriol, A.
    Heffner, L. T.
    Shustik, C.
    Garcia-Sanz, R.
    Cornell, R. F.
    Fernandez de Larrea, C.
    Castillo, J. J.
    Granell, M.
    Kyrtsonis, M. C.
    Leblond, V.
    Symeonidis, A.
    Singh, P.
    Li, J.
    Graef, T.
    Bilotti, E.
    Treon, S.
    Buske, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 82 - 82
  • [2] Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (INNOVATE™)
    Buske, C.
    Trotman, J.
    Tedeschi, A.
    Matous, J., V
    Macdonald, D.
    Tam, C.
    Toumilhac, O.
    Ma, S.
    Oriol, A.
    Heffner, L. T.
    Shustik, C.
    Garcia-Sanz, R.
    Cornell, R. F.
    Fernandez de Larrea, C.
    Castillo, J. J.
    Granell, M.
    Kyrtsonis, M-C
    Leblond, V
    Symeonidis, A.
    Singh, P.
    Li, J.
    Graef, T.
    Bilotti, E.
    Treon, S.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 119 - 119
  • [3] Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenstrom's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE™)
    Dimopoulos, Meletios A.
    Trotman, Judith
    Tedeschi, Alessandra
    Matous, Jeffrey V.
    Macdonald, David
    Tam, Constantine
    Tournilhac, Oliver
    Ma, Shuo
    Oriol, Albert
    Heffner, Leonard T.
    Shustik, Chaim
    Garcia-Sanz, Ramon
    Cornelli, Robert F.
    Fernandez de Larrea, Carlos
    Castillo, Jorge J.
    Granell, Miquel
    Kyrtsonis, Marie-Christine
    Leblond, Veronique
    Svmeonidis, Argiris
    Singh, Priyanka
    Li, Jianling
    Graef, Thorsten
    Bilotti, Elizabeth
    Treon, Steven
    Buske, Christian
    BLOOD, 2015, 126 (23)
  • [4] Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial
    Trotman, Judith
    Buske, Christian
    Tedeschi, Alessandra
    Matous, Jeffrey V.
    MacDonald, David
    Tam, Constantine S.
    Tournilhac, Olivier
    Ma, Shuo
    Treon, Steven P.
    Oriol, Albert
    Ping, Jerry
    Briso, Eva M.
    Arango-Hisijara, Israel
    Dimopoulos, Meletios A.
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5793 - 5800
  • [5] Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstrom Macroglobulinemia (WM)
    Siegel, David S.
    Kaufman, Jonathan L.
    Raje, Noopur S.
    Mikhael, Joseph R.
    Kapoor, Prashant
    Treon, Steven P.
    Castillo, Jorge J.
    Neuman, Linda L.
    Lee, Ju RueyJiuan
    Ghobrial, Irene
    BLOOD, 2014, 124 (21)
  • [6] Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE™ Trial
    Trotman, Judith
    Buske, Christian
    Tedeschi, Alessandra
    Matous, Jeffrey V.
    MacDonald, David
    Tam, Constantine
    Tournilhac, Olivier
    Ma, Shuo
    Treon, Steven P.
    Oriol, Albert
    Ping, Jerry
    Briso, Eva M.
    Arango-Hisijara, Israel
    Dimopoulos, Meletios A.
    BLOOD, 2020, 136
  • [7] Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
    Dimopoulos, Meletios A.
    Trotman, Judith
    Tedeschi, Alessandra
    Matous, Jeff Rey V.
    Macdonald, David
    Tam, Constantine
    Tournilhac, Olivier
    Ma, Shuo
    Oriol, Albert
    Heffner, Leonard T.
    Shustik, Chaim
    Garcia-Sanz, Ramon
    Cornell, Robert F.
    de Larrea, Carlos Fernandez
    Castillo, Jorge J.
    Granell, Miquel
    Kyrtsonis, Marie-Christine
    Leblond, Veronique
    Symeonidis, Argiris
    Kastritis, Efstathios
    Singh, Priyanka
    Li, Jianling
    Graef, Thorsten
    Bilotti, Elizabeth
    Treon, Steven
    Buske, Christian
    LANCET ONCOLOGY, 2017, 18 (02): : 241 - 250
  • [8] A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
    Izutsu, Koji
    Kato, Hisashi
    Sekiguchi, Naohiro
    Fujisaki, Tomoaki
    Kawakita, Toshiro
    Obara, Naoshi
    Matsue, Kosei
    Nishimoto, Mitsutaka
    Hatayama, Tomoyoshi
    Inagaki, Mitsuo
    Fujikawa, Ei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 80 - 90
  • [9] Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial
    Buske, C.
    Tedeschi, A.
    Trotman, J.
    Garcia-Sanz, R.
    MacDonald, D.
    Leblond, V
    Mahe, B.
    Herbaux, C.
    Tam, C. S.
    Palomba, M. L.
    Matous, J., V
    Shustik, C.
    Kastritis, E.
    Treon, S. P.
    Li, J.
    Salman, Z.
    Graef, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 252 - 252
  • [10] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA
    Siegel, D.
    Kaufman, J. L.
    Raje, N.
    Mikhael, J.
    Kapoor, P.
    Treon, S.
    Castillo, J.
    Neuman, L.
    Obreja, M.
    Ghobrial, I.
    HAEMATOLOGICA, 2015, 100 : 461 - 461
12345